Tyrosine kinase inhibitors in the treatment of chronic myeloid leukaemia: So far so good?

Blood Reviews

Volumn 15, Issue 2, 2001, Pages 85-95

  Drummond, M W ^a   Holyoake, T L ^a  

^a GLASGOW ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; GLYCOPROTEIN P; HERBIMYCIN A; IMATINIB; PROTEIN INHIBITOR; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR;

CANCER CELL; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CYTOGENETICS; DRUG STRUCTURE; DRUG TARGETING; FUSION GENE; GENE AMPLIFICATION; HUMAN; IN VITRO STUDY; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PROTEIN FAMILY; REVIEW; SIGNAL TRANSDUCTION;

EID: 0034942219     PISSN: 0268960X     EISSN: None     Source Type: Journal    
DOI: 10.1054/blre.2001.0152     Document Type: Article

References (126)

1. A minute chromosome in human chronic granulocytic leukemia
2. A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining
3. Fused transcript of abl and bcr genes in chronic myelogenous leukaemia
4. The BCR/ABL hybrid gene
5. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells
6. Lymphosarcoma: Virus-induced thymic-independent disease in mice
7. Abl tyrosine protein kinase
8. Modular binding domains in signal transduction proteins
9. N-terminal mutations activate the leukemogenic potential of the myristoylated form of c-abl
10. BCR first exon sequences specifically activate the BCR/ABL tyrosine kinase oncogene of Philadelphia chromosome-positive human leukemias
11. c-Abl has high intrinsic tyrosine kinase activity that is stimulated by mutation of the Src homology of 3 domain and by autophosphorylation at two distinct regulatory tyrosines
12. An actin-binding function contributes to transformation by the Bcr-Abl oncoprotein of Philadelphia chromosome-positive human leukemias
13. Cell cycle-regulated binding of c-Abl tyrosine kinase to DNA
14. The cytostatic function of c-Abl is controlled by multiple nuclear localization signals and requires the p53 and Rb tumor suppressor gene products
15. The mouse type IV c-abl gene product is a nuclear protein, and activation of transforming ability is associated with cytoplasmic localization
16. ml mutation show poor viability and depletion of selective B and T cell populations
17. Neonatal lethality and lymphopenia in mice with a homozygous disruption of the c-abl proto-oncogene
18. Cycling, stressed-out and nervous: Cellular functions of c-Abl
19. A C-terminal protein-binding domain in the retinoblastoma protein regulates nuclear c-abl tyrosine kinase in the cell cycle
20. Abrogation of retinoblastoma protein function by c-Abl through tyrosine kinase-dependent and -independent mechanisms
21. Tyrosine phosphorylation of mammalian RNA polymerase II carboxyl-terminal domain
22. The nuclear tyrosine kinase c-Abl negatively regulates cell growth
23. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours
24. p73 is regulated by tyrosine kinase c-Abl in the apoptotic response to DNA damage
25. p73 is a human p53 related protein that can induce apoptosis
26. Activation of the c-Abl tyrosine kinase in the stress response to DNA-damaging agents
27. Regulation of DNA damage-induced apoptosis by the c-Abl tyrosine kinase
28. Integrins regulate the association and phosphorylation of paxillin by c-Abl
29. c-Abl kinase regulates the protein binding activity of c-Crk
30. Integrin regulation of c-Abl tyrosine kinase activity and cytoplasmic-nuclear transport
31. A novel human gene closely related to the abl proto-oncogene
32. Essential roles for the Abl and Arg tyrosine kinases in neurulation
33. The Arg tyrosine kinase is inhibited by ST1571
34. Increased neutrophil respiratory burst in bcr-null mutants
35. The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype
36. The ABL-BCR fusion gene is expressed in chronic myeloid leukemia
37. The molecular genetics of Philadelphia chromosome-positive leukemias
38. Neutrophilic-chronic myeloid leukemia: A distinct disease with a specific molecular marker (BCR/ABL with C3/A2 junction)
39. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products
40. Analysis of the biologic properties of p230 Bcr-Abl reveals unique and overlapping properties with the oncogenic p185 and p210 Bcr-Abl tyrosine kinases
41. Relationship between BCR/ABL fusion proteins and leukemia phenotype
42. A new case of chronic myeloid leukemia with c3/a2 BCR/ABL junction. Is it really a distinct disease?
43. Typical chronic myelogenous leukemia with el9a2 junction BCR/ABL transcript
44. The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity
45. Recent advances in the molecular and cellular biology of CML: Lessons to be learned from the laboratory
46. CRKL is the major tyrosine phosphorylated protein in neutrophils from patients with chronic myelogenous leukemia
47. The Bcr-Abl leukemia oncogene activates Jun kinase and requires Jun for transformation
48. Genetic requirement for Ras in the transformation of fibroblasts and hematopoietic cells by the bcr-abl oncogene
49. Phosphatidylinositol-3 kinase activity is regulated by BCR/ABL and is required for the growth of Philadelphia chromosome-positive cells
50. C-RAF-I serine/threonine kinase is required in BCR/ABL-dependent and normal hematopoiesis
51. Transformation of hematopoietic cells by BCR/ABL requires activation of a Pl-3k/Akt-dependent pathway
52. Altered adhesive interactions with marrow stroma of haematopoletic progenitor cells in chronic myeloid leukaemia
53. BCR/ABL induces multiple abnormalities of cytoskeletal function
54. bcr/abl gene of the Philadelphia chromosome
55. BCR-ABL efficiently induces a myeloproliferative disease and production of excess interleukin-3 and granulocyte-macrophage colony-stimulating factor in mice: A novel model for chronic myelogenous leukemia
56. Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving a P210 bcr/abl-transduced bone marrow
57. Tyrosine kinase inhibition: An approach to drug development
58. Blocking of EGF-dependent cell proliferation by EGF receptor kinase inhibitors
59. Tyrphostins I: Synthesis and biological activity of protein tyrosine kinase inhibitors
60. In-situ inhibition of tyrosine protein kinase by erbstatin
61. Inhibition of platelet-derived growth factor induced mitogenesis and tyrosine-kinase activity in cultured bone marrow fibroblasts by tyrphostins
62. Specific inhibitors of tyrosine-specific protein kinases: Properties of 4-hydroxycinnamamide derivatives in vitro
63. Tyrphostins: Tyrosine kinase blockers as novel antiproliferative agents and dissectors of signal transduction
64. bcr-abl tyrosine kinase activity induces K562 to differentiate
65. Tyrphostin AG957, a tyrosine kinase inhibitor with anti-BCR/ABL tyrosine kinase activity restores beta I integrin-mediated adhesion and inhibitory signaling in chronic myelogenous leukaemia hematopoietic progenitors
66. + chronic myeloid leukemia progenitor cells
67. Inhibition of transforming activity of tyrosine kinase oncogenes by herbimycin A
68. Induction of erythyroid differentiation of K562 human leukaemic cells by herbimycin A, an inhibitor of tyrosine kinase activity
69. Tyrosine kinase inhibitor-induced differentiation of K562 cells: Alterations of cell cycle and cell surface phenotype
70. Effect of herbimycin A, an antagonist of tyrosine kinase, on bcr/abl oncoprotein-associated cell proliferations: Abrogative effect on the transformation of murine hematopoietic cells by transfection of a retroviral vector expressing oncoprotein P210 bcr/abl and preferential inhibition on Ph-I-positive leukemia cell growth
71. Treatment of Philadelphia-chromosome positive human leukemia in SCID mouse model with herbimycin A, a bcr-abl tyrosine kinase activity inhibitor
72. Genistein, a specific inhibitor of tyrosine-specific protein kinases
73. Selection of myeloid progenitors lacking BCR-ABL mRNA in chronic myelogenous leukemia patients after in-vitro treatment with the tyrosine kinase inhibitor genistein
74. Benzopyranones and benzothiopyranones: A class of tyrosine protein kinase inhibitors with selectivity for the v-abl kinase
75. Discovery of a novel Abl tyrosine kinase inhibitor that selectively induces apoptosis of Bcr-Abl positive leukemic cells
76. Selective inhibition of the platelet-derived growth factor signal transduction pathway by a protein-tyrosine kinase inhibitor of the 2-phenylaminopyrimidine class
77. Generation of fibrosarcomas in vivo by a retrovirus that expresses the normal B chain of platelet-derived growth factor and mimics the alternative splice pattern of the v-sis oncogene
78. Platelet-derived growth factor in autocrine transformation
79. Platelet-derived growth factor
80. Tyrphostins inhibit PDGF-induced DNA synthesis and associated early events in smooth muscle cells
81. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative
82. The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells
83. Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL leukemic cells and induces apoptosis
84. The tyrosine kinase inhibitor ST1571, like interferon-alpha, preferentially reduces the capacity for amplification of granulocyte-macrophage progenitors from patients with chronic myeloid leukemia
85. Blockade of the BCR-ABL kinase activity induces apoptosis of chronic myelogenous leukemia cells by suppressing signal transducer and activator of transcription 5-dependent expression of BCL-xL
86. Activation of the Abelson tyrosine kinase activity is associated with suppression of apoptosis in hemopoietic cells
87. BCR-ABL-mediated inhibition of apoptosis with delay of G2/M transition after DNA damage: A mechanism of resistance to multiple anticancer agents
88. CGP57148B (ST1571) induces differentiation and apoptosis and sensitizes Bcr-Abl-positive human leukemia cells to apoptosis due to antileukemic drugs
89. In vivo eradication of human BCR/ABL-positive leukemia cells with an ABL kinase inhibitor
90. The tyrosine kinase inhibitor ST1571 prolongs survival in a murine model of chronic myelogenous leukemia
91. CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins
92. r 190,000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57148)
93. TEL/PDGFbetaR induces hematologic malignancies in mice that respond to a specific tyrosine kinase inhibitor
94. Inhibition of c-kit receptor tyrosine kinase activity by ST1571, a selective tyrosine kinase inhibitor
95. Autocrine growth of small cell lung cancer mediated by co-expression of c-kit and stem cell factor
96. Activating c-kit gene mutations in human germ cell tumors
97. Expression of stem cell factor and its receptor by human neuroblastoma cells and tumors
98. In vivo differentiation of mast cells from acute myeloid leukaemia blasts carrying a novel activating ligand-independent c-kit mutation
99. Stem cell factor induces proliferation and differentiation of highly enriched murine hematopoietic cells
100. Requirement for mast cell growth factor for primordial germ cell survival in culture
101. Lessons learned from the development of an Abl tyrosine kinase inhibitor for chronic myelogenous leukemia
102. Genetic analysis of the ATP binding sites of HCK and ABL kinases reveal distinct and overlapping determinants for the specificity of the tyrosine kinase inhibitors PPI and ST1571
103. Analysis of the structural basis of specificity of inhibition of the Abl kinase by ST1571
104. BCR-ABL-specific tyrosine kinase inhibitor; activity on lineage-commited and primitive chronic myelogenous leukemia progenitors
105. Clinical efficacy and safety of an ABL specific tyrosine kinase inhibitor as targeted therapy for chronic myeloid leukemia
106. Phase II study of ST1571, a tyrosine kinase inhibitor, in patients with resistant or refractory Philadelphia chromosome-positive chronic myeloid leukemia
107. A Phase II study of ST1571 in adult patients with Philadelphia chromosome positive chronic myeloid leukemia in accelerated phase
108. Activity of an ABL specific tyrosine kinase inhibitor in patients with chronic myeloid leukemia in blast crisis and other Philadelphia chromosome positive acute leukemias
109. A Phase II study to determine the safety and anti-leukaemic effects of ST1571 in adult patients with Philadelphia chromosome positive acute leukemias
110. Value of interphase fluorescent in-situ hybridisation (iFISH) studies in monitoring response to ST1571 therapy in patients with Philadelphia chromosome positive chronic myelogenous leukemia
111. PCR-negative molecular remissions in chronic-accelerated-, and blast crisis-phase CML patients treated with ST1571, an ABL-specific kinase inhibitor
112. Monitoring the response of CML patients treated with ST1571 by molecular cytogenetics and quantitative RT-PCR
113. Mechanism of resistance to the ABL tyrosine kinase inhibitor ST1571 in BCR/ABL -transformed hematopoietic cell lines
114. Selection and characterisation of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor ST1571: Diverse mechanisms of resistance
115. Relapse in Ph+ leukemia patients treated with an Abl-specific kinase inhibitor is associated with reactivation of Bcr-Abl
116. BCR/ABL gene amplification: A possible mechanism of drug resistance in patients treated with an abl-specific kinase inhibitor
117. Role of alpha-I acid glycoprotein in the in-vivo resistance of human Bcr-Abl+ leukemic cells to the Abl inhibitor ST1571
118. Elevated levels of the plasma glycoprotein, alpha-I-acid glycoprotein (AGP) in patients with CML should not mediate resistance to ST1571
119. Isolation of a highly quiescent subpopulation of primitive leukemic cells in chronic myeloid leukemia
120. + progenitor cells survive exposure to ST1571 independent of their position in cell cycle
121. Efficacy of ST1571, an Abl tyrosine kinase inhibitor, in conjunction with other antileukemic agents against Bcr-Abl-positive cells
122. In vitro cytotoxic effects of a tyrosine kinase inhibitor ST1571 in combination with commonly used antileukemic agents
123. Inhibition of juvenile myelomonocytic leukemia cell growth in vitro by farnesyltransferase inhibitors
124. Activity of the farnesyl protein transferase inhibitor SCH66336 against BCR/ABL-induced murine leukemia and primary cells from patients with chronic myeloid leukemia
125. Comparison of effects of the tyrosine kinase inhibitors AG957, AG490 and ST1571 on BCR-ABL-expressing cells, demonstrating synergy between AG490 and ST1571
126. Evolution of bone marrow transplantation-the original immunotherapy